LTRN vs ONCO vs CASI

For growth investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger pick with -15. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lantern Pharma Inc.

(LTRN) delivered a total return of -86. 1%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: LTRN returned -86. 0% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 22β versus Lantern Pharma Inc. 's 2. 49β — meaning LTRN is approximately -1220% more volatile than CASI relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CASI Pharmaceuticals, Inc.

(CASI) is pulling ahead at -15. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to -1312. 6% for Lantern Pharma Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantern Pharma Inc.

(LTRN) is the more profitable company, earning 0. 0% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LTRN leads at 0. 0% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ONCO (34.

1% yield), CASI (31. 1% yield) pay a dividend. LTRN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 22), 31. 1% yield). Lantern Pharma Inc. (LTRN) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -99. 0%, LTRN: -86. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LTRN is a small-cap quality compounder stock; ONCO is a small-cap income-oriented stock; CASI is a small-cap income-oriented stock. ONCO, CASI pay a dividend while LTRN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.